Oruka Therapeutics (ORKA) Competitors $15.44 -0.12 (-0.77%) Closing price 04:00 PM EasternExtended Trading$15.42 -0.01 (-0.10%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA vs. AGIO, IDYA, HRMY, OCUL, RXRX, IRON, BLTE, MESO, CGON, and ANIPShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Harmony Biosciences (HRMY), Ocular Therapeutix (OCUL), Recursion Pharmaceuticals (RXRX), Disc Medicine (IRON), Belite Bio (BLTE), Mesoblast (MESO), CG Oncology (CGON), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Its Competitors Agios Pharmaceuticals IDEAYA Biosciences Harmony Biosciences Ocular Therapeutix Recursion Pharmaceuticals Disc Medicine Belite Bio Mesoblast CG Oncology ANI Pharmaceuticals Oruka Therapeutics (NASDAQ:ORKA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Do insiders & institutionals hold more shares of ORKA or AGIO? 56.4% of Oruka Therapeutics shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ORKA or AGIO? Oruka Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Does the media prefer ORKA or AGIO? In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 2 mentions for Oruka Therapeutics. Agios Pharmaceuticals' average media sentiment score of 1.57 beat Oruka Therapeutics' score of 1.49 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation & earnings, ORKA or AGIO? Agios Pharmaceuticals has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$83.72M-$2.81-5.49Agios Pharmaceuticals$36.50M64.64$673.72M$11.003.69 Is ORKA or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Oruka Therapeutics' net margin of 0.00%. Agios Pharmaceuticals' return on equity of -3.49% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -26.26% -24.16% Agios Pharmaceuticals 1,590.42%-3.49%-3.23% Do analysts prefer ORKA or AGIO? Oruka Therapeutics presently has a consensus price target of $40.38, suggesting a potential upside of 161.50%. Agios Pharmaceuticals has a consensus price target of $56.33, suggesting a potential upside of 38.72%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryAgios Pharmaceuticals beats Oruka Therapeutics on 10 of the 16 factors compared between the two stocks. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$554.27M$2.51B$5.77B$9.77BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-5.4922.6482.3726.60Price / SalesN/A714.67536.82175.38Price / CashN/A26.3325.7028.92Price / Book1.706.7910.646.56Net Income-$83.72M$32.94M$3.28B$266.04M7 Day Performance1.71%0.75%-0.08%-0.58%1 Month Performance13.53%8.36%10.36%6.24%1 Year PerformanceN/A0.53%49.00%22.21% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics2.7785 of 5 stars$15.44-0.8%$40.38+161.5%N/A$554.27MN/A-5.49N/ANews CoveragePositive NewsGap DownAGIOAgios Pharmaceuticals4.3533 of 5 stars$37.47+0.6%$56.33+50.4%-14.5%$2.18B$36.50M3.41390News CoveragePositive NewsIDYAIDEAYA Biosciences4.4106 of 5 stars$24.75+0.1%$48.09+94.3%-35.5%$2.17B$7M-6.5480News CoveragePositive NewsAnalyst ForecastHRMYHarmony Biosciences4.2812 of 5 stars$37.22-0.5%$51.00+37.0%+3.1%$2.14B$772.53M12.00200Positive NewsOCULOcular Therapeutix3.5489 of 5 stars$12.10+2.0%$17.20+42.1%+44.0%$2.10B$63.72M-9.45230RXRXRecursion Pharmaceuticals2.1056 of 5 stars$4.86+0.5%$7.00+44.2%-36.0%$2.10B$58.84M-2.72400Positive NewsIRONDisc Medicine3.2643 of 5 stars$59.66+0.4%$98.30+64.8%+20.8%$2.07BN/A-13.3330News CoveragePositive NewsBLTEBelite Bio2.6731 of 5 stars$64.71+1.7%$96.67+49.4%+34.3%$2.06BN/A-41.7510Positive NewsMESOMesoblast2.1947 of 5 stars$15.91+1.2%$18.00+13.2%+94.7%$2.04B$5.90M0.0080News CoverageCGONCG Oncology3.0286 of 5 stars$26.61+4.7%$55.27+107.7%-25.5%$2.03B$551K-15.0561News CoverageAnalyst UpgradeANIPANI Pharmaceuticals3.6726 of 5 stars$91.15+0.9%$84.75-7.0%+47.6%$1.98B$614.38M-118.37600News Coverage Related Companies and Tools Related Companies AGIO Competitors IDYA Competitors HRMY Competitors OCUL Competitors RXRX Competitors IRON Competitors BLTE Competitors MESO Competitors CGON Competitors ANIP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Orphaned Well Crisis Hidden Across AmericaAcross the U.S., millions of abandoned oil and gas wells are leaking methane into the air — a costly and dange...The Tomorrow Investor | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
